These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7049504)

  • 1. Sulindac disposition when given once and twice daily.
    Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
    Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A kinetic study of sulindac in the elderly.
    Bayley N; Warne RW; Moulds RF; Bury RW
    Aust N Z J Med; 1987 Feb; 17(1):39-42. PubMed ID: 3476045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl sulfoxide inhibits bioactivation of sulindac.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    J Lab Clin Med; 1983 Jul; 102(1):95-101. PubMed ID: 6854139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
    Sitar DS; Owen JA; MacDougall B; Hunter T; Mitenko PA
    Clin Pharmacol Ther; 1985 Aug; 38(2):228-34. PubMed ID: 4017423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state disposition of diflunisal: once- versus twice-daily administration.
    Mojaverian P; Rocci ML; Swanson BN; Vlasses PH; Chremos AN; Lin JH; Yeh JC; Ferguson RK
    Pharmacotherapy; 1985; 5(6):336-9. PubMed ID: 3841206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening.
    Marathe PH; Lee JS; Greene DS; Barbhaiya RH
    Br J Clin Pharmacol; 1996 Jan; 41(1):21-7. PubMed ID: 8824689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension.
    Koopmans PP; Thien T; Thomas CM; Van den Berg RJ; Gribnau FW
    Br J Clin Pharmacol; 1986 Apr; 21(4):417-23. PubMed ID: 3518773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The disposition of sulindac.
    Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC
    Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulindac metabolism: the importance of an intact colon.
    Strong HA; Warner NJ; Renwick AG; George CF
    Clin Pharmacol Ther; 1985 Oct; 38(4):387-93. PubMed ID: 4042521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulindac is not renal sparing in man.
    Roberts DG; Gerber JG; Barnes JS; Zerbe GO; Nies AS
    Clin Pharmacol Ther; 1985 Sep; 38(3):258-65. PubMed ID: 4028619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa.
    Graham DY; Smith JL; Holmes GI; Davies RO
    Clin Pharmacol Ther; 1985 Jul; 38(1):65-70. PubMed ID: 3874038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of indomethacin and sulindac on hydrochlorothiazide kinetics.
    Koopmans PP; Kateman WG; Tan Y; van Ginneken CA; Gribnau FW
    Clin Pharmacol Ther; 1985 Jun; 37(6):625-8. PubMed ID: 3891188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.